DK3280416T3 - Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere - Google Patents

Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere Download PDF

Info

Publication number
DK3280416T3
DK3280416T3 DK16777058.5T DK16777058T DK3280416T3 DK 3280416 T3 DK3280416 T3 DK 3280416T3 DK 16777058 T DK16777058 T DK 16777058T DK 3280416 T3 DK3280416 T3 DK 3280416T3
Authority
DK
Denmark
Prior art keywords
paliperid
easters
injective
lacking
doses
Prior art date
Application number
DK16777058.5T
Other languages
Danish (da)
English (en)
Inventor
Srihari Gopal
Paulien Gerarda Maria Ravenstijn
Alberto Russu
Mahesh Narain Samtani
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3280416(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3280416T3 publication Critical patent/DK3280416T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK16777058.5T 2015-04-07 2016-03-30 Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere DK3280416T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US201562162596P 2015-05-15 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
DK3280416T3 true DK3280416T3 (da) 2020-05-11

Family

ID=57072843

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16777058.5T DK3280416T3 (da) 2015-04-07 2016-03-30 Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere
DK20169861.0T DK3744326T3 (da) 2015-04-07 2016-03-30 Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20169861.0T DK3744326T3 (da) 2015-04-07 2016-03-30 Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere

Country Status (27)

Country Link
US (1) US10143693B2 (OSRAM)
EP (3) EP4349323A3 (OSRAM)
JP (3) JP6728221B2 (OSRAM)
KR (3) KR102755145B1 (OSRAM)
AU (4) AU2016244801B2 (OSRAM)
BR (1) BR112017021383A2 (OSRAM)
CA (2) CA3088401A1 (OSRAM)
CY (1) CY1123203T1 (OSRAM)
DK (2) DK3280416T3 (OSRAM)
EA (1) EA037185B1 (OSRAM)
ES (2) ES2802299T3 (OSRAM)
FI (1) FI3744326T3 (OSRAM)
HR (2) HRP20240022T1 (OSRAM)
HU (2) HUE049485T2 (OSRAM)
IL (3) IL254669B2 (OSRAM)
LT (2) LT3280416T (OSRAM)
MA (1) MA41917B1 (OSRAM)
MD (2) MD3280416T2 (OSRAM)
NZ (1) NZ735952A (OSRAM)
PL (2) PL3280416T3 (OSRAM)
PT (2) PT3744326T (OSRAM)
RS (2) RS65024B1 (OSRAM)
SI (2) SI3280416T1 (OSRAM)
SM (2) SMT202000351T1 (OSRAM)
TW (1) TWI694825B (OSRAM)
UA (1) UA118732C2 (OSRAM)
WO (1) WO2016164218A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2802299T3 (es) 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada
CA3077224A1 (en) 2017-10-27 2019-05-02 Shandong Luye Pharmaceutical Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
EP4385564A3 (en) * 2020-11-30 2024-10-09 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
JP2023551007A (ja) * 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ.ベー. パルミチン酸パリペリドン製剤の再懸濁を確実にする方法
EP4025189B1 (en) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
DK4025188T3 (da) * 2020-11-30 2024-03-04 Janssen Pharmaceutica Nv Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
CA3229731A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
IL311134A (en) * 2021-08-30 2024-04-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release paliperidone injection formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
SI2234617T2 (sl) * 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
US8758780B2 (en) * 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
CA2742393A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
PT2529757E (pt) * 2011-05-31 2014-02-27 Rovi Lab Farmaceut Sa Formulação para implante de paliperidona
ES2802299T3 (es) 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada

Also Published As

Publication number Publication date
SI3280416T1 (sl) 2020-07-31
US20170281629A1 (en) 2017-10-05
ES2802299T3 (es) 2021-01-18
PT3280416T (pt) 2020-06-30
LT3280416T (lt) 2020-06-25
TWI694825B (zh) 2020-06-01
AU2016244801A1 (en) 2017-10-05
PL3744326T3 (pl) 2024-03-25
AU2024227790A1 (en) 2024-11-21
AU2020239611B2 (en) 2022-07-21
LT3744326T (lt) 2023-12-27
IL309340A (en) 2024-02-01
EA037185B1 (ru) 2021-02-17
SMT202000351T1 (it) 2020-09-10
JP2018510894A (ja) 2018-04-19
RS65024B1 (sr) 2024-01-31
MD3280416T2 (ro) 2020-10-31
HUE049485T2 (hu) 2020-09-28
JP7422277B2 (ja) 2024-01-26
SMT202300478T1 (it) 2024-01-10
US10143693B2 (en) 2018-12-04
KR102606678B1 (ko) 2023-11-24
AU2016244801B2 (en) 2020-06-25
UA118732C2 (uk) 2019-02-25
NZ758246A (en) 2024-05-31
EP4349323A2 (en) 2024-04-10
EP3280416A4 (en) 2019-01-23
AU2022221405B2 (en) 2024-08-01
HK1249047A1 (en) 2018-10-26
EP4349323A3 (en) 2024-06-12
CA3088401A1 (en) 2016-10-07
CA2925908C (en) 2020-09-01
MD3744326T2 (ro) 2024-05-31
EP3280416B1 (en) 2020-04-22
SI3744326T1 (sl) 2024-02-29
AU2020239611A1 (en) 2020-10-15
KR20170134583A (ko) 2017-12-06
JP2021130680A (ja) 2021-09-09
PL3280416T3 (pl) 2020-12-14
AU2022221405A1 (en) 2022-09-15
KR20230162162A (ko) 2023-11-28
WO2016164218A1 (en) 2016-10-13
ES2967585T3 (es) 2024-05-03
IL254669B1 (en) 2024-01-01
CY1123203T1 (el) 2021-10-29
IL254669B2 (en) 2024-05-01
FI3744326T3 (fi) 2024-02-02
MA41917B1 (fr) 2020-07-29
EP3280416A1 (en) 2018-02-14
NZ735952A (en) 2022-02-25
KR20250013293A (ko) 2025-01-31
JP6728221B2 (ja) 2020-07-22
JP2020090498A (ja) 2020-06-11
EP3744326B1 (en) 2023-12-06
PT3744326T (pt) 2024-01-15
JP7228503B2 (ja) 2023-02-24
EP3744326A1 (en) 2020-12-02
IL324059A (en) 2025-12-01
BR112017021383A2 (pt) 2018-07-03
IL254669A0 (en) 2017-11-30
HRP20201027T1 (hr) 2020-12-11
DK3744326T3 (da) 2024-02-05
EA201792209A1 (ru) 2018-02-28
RS60510B1 (sr) 2020-08-31
CA2925908A1 (en) 2016-10-07
KR102755145B1 (ko) 2025-01-14
HRP20240022T1 (hr) 2024-03-29
HUE065435T2 (hu) 2024-05-28
TW201642863A (zh) 2016-12-16

Similar Documents

Publication Publication Date Title
DK3280416T3 (da) Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere
EP3754089C0 (de) Dosiereinrichtung
HUE048644T2 (hu) Adagoló rendszer
PL3131533T3 (pl) Doustna postać dawkowania ketaminy
DK3310231T3 (da) Doseringsindretning
HUE043290T2 (hu) Adagoló kapszula
DK3220892T3 (da) Langtidsvirkende væksthormondoseringsformer
DK3325051T3 (da) Variabel enkeltdosisinjektor
IL258525A (en) Dosing regimens
ES1162584Y (es) Aparato dosificador
IL259101A (en) Melflufen dosage regimens for cancer
PL3609808T3 (pl) Pojemnik dozujący
PT3126791T (pt) Dispositivo doseador
HUE049494T2 (hu) Vetõmag adagolás
EP3600836A4 (en) ENERGY DOSAGE FOR ADDITIVE MANUFACTURING
FR3030466B3 (fr) Valve doseuse multilame
EP3810063A4 (en) Individual dose pack
HUE065920T2 (hu) Kupakok referenciás adagolása
IL269169A (en) Novel dosage form
DE112015005590A5 (de) Dosierpumpe
ITUB20152349A1 (it) Metodo di dosaggio autocalibrato
DK3288967T3 (da) Farmaceutisk forbindelse
PL3215437T3 (pl) Urządzenie dozujące
EP3441975C0 (en) DOSING UNIT RECHARGE SCHEDULE
ES1178835Y (es) Envase dosificador